We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

7 analysts have shared their evaluations of Voyager Therapeutics VYGR during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a concise ...

Corcept Therapeutics (CORT) announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in patients with platinum-resistant ...

Digital therapeutics coupled with drugs has the potential to transform health care and change the way patients are treated, Anthony Costello, CEO of Medidata Solutions Inc., told BioWorld. Medidata ...

RNA therapeutics have existed since the late 90s but have only come into focus in the last few years. This renewed interest has largely been attributed to the success of messenger RNA (mRNA) vaccines ...

Lyndra Therapeutics, which spun out of Moderna co-founder Robert Langer’s lab at the Massachusetts Institute of Technology in 2015, is winding down operations this week, a person with knowledge ...

The FDA has approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release tablets to treat hyperphagia in individuals aged four years and older with Prader-Willi syndrome (PWS). The ...

The Motley Fool has positions in and recommends Merck and Summit Therapeutics. The Motley Fool has a disclosure policy. 2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a ...

Summit Therapeutics (NASDAQ:SMMT) traded higher in the premarket on Wednesday after Citi upgraded the stock to Buy from Neutral, becoming the latest brokerage to issue a bullish view on the cancer ...

NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced ...

NEWARK, N.J. - Rafael Holdings, Inc. (NYSE: RFL) has successfully completed its business combination with Cyclo Therapeutics, Inc. (NASDAQ: CYTH), as announced today ...

Insiders were net buyers of CRISPR Therapeutics AG's (NASDAQ:CRSP ) stock during the past year. That is, insiders bought more stock than they sold. Although we don't think shareholders should ...